Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful ...

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful valve surgery. The condition is more common in women and younger patients ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...